Cadrenal Therapeutics, Inc. Common Stock (CVKD) vs Ernexa Therapeutics Inc. (ERNA)
A side-by-side comparison of Cadrenal Therapeutics, Inc. Common Stock and Ernexa Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$1.03HealthcareDelayed quote: Oct 6, 2026, 3:40 PM EDT
ERNA
Ernexa Therapeutics Inc.
$2.21HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — CVKD vs ERNA
growth of $100 · dividends reinvested · last 4yCVKD -98.5% (-64.8%/yr)ERNA -99.9% (-80.4%/yr)CVKD compounded faster over this window
Log scale — wide-divergence pair
CVKD ERNA
CVKD vs ERNA: by the numbers
- •CVKD is the larger company ($4M vs $4M market cap).
Metrics side by side
Valuation
| Metric | CVKD | ERNA |
|---|---|---|
| P/B ratio | 0.90 | 1.13 |
Profitability
| Metric | CVKD | ERNA |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -282.13% | -383.03% |
| ROIC | -284.81% | -346.94% |
Growth (annualized)
| Metric | CVKD | ERNA |
|---|---|---|
| Total return CAGR (5Y) | N/A | -86.83% |
Go deeper
Dig into the metrics
Cadrenal Therapeutics, Inc. Common Stock ROEErnexa Therapeutics ROECadrenal Therapeutics, Inc. Common Stock operating marginErnexa Therapeutics operating marginCadrenal Therapeutics, Inc. Common Stock revenue growthErnexa Therapeutics revenue growthCadrenal Therapeutics, Inc. Common Stock free cash flowErnexa Therapeutics free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.